Walvax Biotechnology Co.,Ltd.(300142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300142 Walvax Biotechnology Co.,Ltd.

Closed 12-12 15:00:00

11.31

-0.02

-0.18%

High11.39	Low11.27	Vol18.46M
Open11.38	D1 Closing11.33	Amplitude1.06%
Mkt Cap18.08B	Tradable Cap17.60B	Total Shares1.60B
T/O209.00M	T/O Rate1.19%	Tradable Shares1.56B
P/B1.87	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"Walvax Biotechnology Co.,Ltd.","latestPrice":11.31,"timestamp":1765522998000,"preClose":11.33,"halted":0,"volume":18458173,"delay":0,"changeRate":-0.0018,"floatShares":1556000000,"shares":1599000000,"eps":0.0308,"marketStatus":"Closed","change":-0.02,"latestTime":"12-12 15:00:00","open":11.38,"high":11.39,"low":11.27,"amount":209000000,"amplitude":0.0106,"askPrice":11.32,"askSize":455,"bidPrice":11.31,"bidSize":498,"shortable":0,"etf":0,"ttmEps":0.0308,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":11.33,"symbolType":"stock","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":12.46,"lowLimit":10.2,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":1.87,"roa":"--","peRate":367.207792,"roe":"1.72%","epsLYR":0.0889,"committee":0.215203,"marketValue":18089000000,"turnoverRate":0.0119,"status":1,"floatMarketCap":17598000000},"requestUrl":"/m/hq/s/300142/wiki","defaultTab":"wiki","newsList":[{"id":"1182511579","title":"Walvax Biotechnology (300142.SZ) Receives Approval for Clinical Trials of Freeze-Dried mRNA Vaccine Against Herpes Zoster Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=1182511579","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182511579?lang=en_us&edition=fundamental","pubTime":"2025-12-12 18:46","pubTimestamp":1765536373,"startTime":"0","endTime":"0","summary":"Walvax Biotechnology Co.,Ltd. (300142.SZ) announced that its subsidiaries—Beijing Walvax Innovative Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Walvax Biotechnology Co.,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300142","BK0046","BK0077","BK0070","159646"],"gpt_icon":0},{"id":"1102599580","title":"Walvax Biotechnology Discloses Shareholder Count in Periodic Reports as Required by Regulations","url":"https://stock-news.laohu8.com/highlight/detail?id=1102599580","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102599580?lang=en_us&edition=fundamental","pubTime":"2025-11-27 20:01","pubTimestamp":1764244907,"startTime":"0","endTime":"0","summary":"Walvax Biotechnology Co.,Ltd. stated on November 27 in response to investor inquiries on the interactive platform that the company discloses the number of shareholders at the end of each reporting period in its periodic reports in accordance with relevant laws and regulatory documents.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300142","BK0070","BK0077","BK0046","BK0239"],"gpt_icon":0},{"id":"2586210464","title":"Walvax Biotechnology Gets Egypt Marketing Approval for 13-Valent Pneumococcal Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2586210464","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586210464?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:14","pubTimestamp":1764231294,"startTime":"0","endTime":"0","summary":"Walvax Biotechnology  subsidiary Yuxi Walvax received marketing authorization from Egypt's drug regulator for its 13-valent pneumococcal conjugate vaccine,The vaccine, which protects against 13 serotypes responsible for serious infections, is intended for children aged six weeks to under five years, according to a Thursday filing with the Shenzhen bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0077","BK0070","BK0239","300142","BK0046"],"gpt_icon":0},{"id":"1188281504","title":"Walvax Biotechnology's Subsidiary Receives Egyptian Marketing Authorization for 13-Valent Pneumococcal Conjugate Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1188281504","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188281504?lang=en_us&edition=fundamental","pubTime":"2025-11-26 16:46","pubTimestamp":1764146775,"startTime":"0","endTime":"0","summary":"Walvax Biotechnology Co.,Ltd. (300142.SZ) announced that its subsidiary, Yuxi Walvax Biotechnology Co., Ltd., has obtained the \"Biological Product Marketing Authorization\" from the Egyptian Drug...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300142","BK0046","BK0077","BK0070","159646"],"gpt_icon":0},{"id":"1105010595","title":"HK Stock Movement | MIRXES-B (02629) Rises Over 5% in Afternoon Trading on Partnership with Walvax to Build RNA-Centric Precision Medicine Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1105010595","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105010595?lang=en_us&edition=fundamental","pubTime":"2025-11-21 13:48","pubTimestamp":1763704100,"startTime":"0","endTime":"0","summary":"MIRXES-B (02629) surged more than 5% in afternoon trading. At the time of writing, the stock was up 3.44% to HK$52.55, with a turnover of HK$32.73 million. The company announced it recently signed a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK0046","BK4139","BK4505","RNA","BK0077","02629","BK1161","BK0070","BK0239","BK4585","BK4588","300142"],"gpt_icon":0},{"id":"2584098213","title":"Mirxes Holding Signs Strategic RNA Medicine Partnership with Walvax","url":"https://stock-news.laohu8.com/highlight/detail?id=2584098213","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584098213?lang=en_us&edition=fundamental","pubTime":"2025-11-18 16:34","pubTimestamp":1763454888,"startTime":"0","endTime":"0","summary":"Mirxes Holding Co. Ltd. has announced that it has entered into a memorandum of understanding  with Walvax Biotechnology Co., Ltd., a leading Chinese biopharmaceutical enterprise specializing in vaccines. The two-year strategic partnership aims to leverage both companies' complementary strengths to create an RNA-centric preventive and precision medicine platform. The collaboration will focus on joint development, clinical trials, registration, sales, and distribution of medical solutions, with the goal of advancing early detection and preventive medicine. However, shareholders and potential investors are advised that the collaboration under the MOU may or may not proceed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL99hXHx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0077","BK1161","BK0070","BK0239","BK0046","02629","300142"],"gpt_icon":0},{"id":"1162452129","title":"RSV Outbreak Drives Surge in Prevention Demand as Companies Race to Capture Infant Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1162452129","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162452129?lang=en_us&edition=fundamental","pubTime":"2025-10-12 08:02","pubTimestamp":1760227353,"startTime":"0","endTime":"0","summary":"As respiratory diseases enter their peak season, discussions about \"Respiratory Syncytial Virus (RSV)\" continue to surge across major social media platforms. According to surveillance data released...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0077","688276","LU2580892862.HKD","BK1515","300142","BK0070","BK1161","LU2148510915.USD","02257","06660","LU2580892789.USD","BK0196","BK0239","BK1574","LU1064131003.USD","159982","300122","BK0046","LU1064130708.USD","01672","LU1328615791.USD","688443"],"gpt_icon":0},{"id":"2571534113","title":"Walvax Biotechnology Subsidiary Gets Jordan Approval for 13-Valent Pneumococcal Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2571534113","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571534113?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:18","pubTimestamp":1759231092,"startTime":"0","endTime":"0","summary":"Walvax Biotechnology  subsidiary Yuxi Walvax Biotechnology obtained drug registration approval from Jordan for its 13-valent pneumococcal polysaccharide conjugate vaccine, according to a Tuesday filing with the Shenzhen bourse.The vaccine is indicated for infants and children aged six months to five years for the prevention of 13 pneumococcal types, the filing said.Pneumococcal infections are among the leading causes of death in children and infants worldwide, according to the vaccine manufacturer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300142","BK0070","BK0077","BK0046","BK0239"],"gpt_icon":0},{"id":"1117582990","title":"An Unusual Scene in the Vaccine Industry Winter: Walvax Biotechnology Distributes More Dividends Than Profits Despite Heavy Losses!","url":"https://stock-news.laohu8.com/highlight/detail?id=1117582990","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117582990?lang=en_us&edition=fundamental","pubTime":"2025-08-27 17:41","pubTimestamp":1756287686,"startTime":"0","endTime":"0","summary":"When a company's net profit plunges 74.69% yet still insists on distributing dividends exceeding its annual profit to shareholders, this scene is unfolding in the brutal \"red ocean\" competition of...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300142","BK0070","BK0077","BK0046","159646"],"gpt_icon":0},{"id":"2562202661","title":"Walvax Biotechnology H1 Profit Down 75%, Revenue Declines 19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562202661","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562202661?lang=en_us&edition=fundamental","pubTime":"2025-08-26 14:05","pubTimestamp":1756188335,"startTime":"0","endTime":"0","summary":"Walvax Biotechnology  posted first-half attributable net profit of 43.2 million yuan, down 75% from 170.6 million yuan the previous year.Earnings per share went up to 0.0273 yuan from 0.1066 yuan, according to a Tuesday filing with the Shenzhen bourse.The pharmaceutical company's operating revenue declined 19% year over year to 1.15 billion yuan from 1.43 billion yuan.Shares of the company slipped 1% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300142"],"gpt_icon":0},{"id":"2556808793","title":"Walvax Biotechnology Gets Regulatory Acceptance for RSV Vaccine Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2556808793","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556808793?lang=en_us&edition=fundamental","pubTime":"2025-08-04 14:20","pubTimestamp":1754288447,"startTime":"0","endTime":"0","summary":"Walvax Biotechnology  said China's medical products administrator accepted its clinical trial application for a respiratory syncytial virus  mRNA vaccine.The vaccine targets lower respiratory tract infections caused by RSV, according to a Monday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 2% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300142","BK0046","BK0070","BK0239","BK0077"],"gpt_icon":0},{"id":"2555042570","title":"Walvax Biotechnology Amends Sub-License Deal With Notitia Biotechnologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2555042570","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555042570?lang=en_us&edition=fundamental","pubTime":"2025-07-31 15:47","pubTimestamp":1753948038,"startTime":"0","endTime":"0","summary":"Walvax Biotechnology  amended its exclusive sub-license with US-based Notitia Biotechnologies, according to a Thursday filing with the Shenzhen bourse.The addition includes non-patient applications of core microbiome analysis, microbiota-targeted transplantation and nutritional formulation technologies in China, Hong Kong and Macau.Walvax Biotechnology will pay $1.5 million in upfront fees and 6.5% royalties as well as milestone payments related to approvals and sales targets.Shares of the pharmaceutical company were down 2% Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0077","BK0070","BK0046","300142"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","stockEarnings":[{"period":"1week","weight":-0.0342},{"period":"1month","weight":-0.1073},{"period":"3month","weight":-0.0908},{"period":"6month","weight":0.1088},{"period":"1year","weight":-0.2105},{"period":"ytd","weight":-0.0628}],"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","perCapita":"13643股","boardName":"医药制造业","registeredCapital":"159934万元","compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"survey":"　　云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是人用疫苗。","serverTime":1765736111685,"listedPrice":95,"stockholders":"114040人(较上一季度减少2.75%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Walvax Biotechnology Co.,Ltd.(300142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Walvax Biotechnology Co.,Ltd.(300142) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Walvax Biotechnology Co.,Ltd.,300142,Walvax Biotechnology Co.,Ltd.股票,Walvax Biotechnology Co.,Ltd.股票老虎,Walvax Biotechnology Co.,Ltd.股票老虎国际,Walvax Biotechnology Co.,Ltd.行情,Walvax Biotechnology Co.,Ltd.股票行情,Walvax Biotechnology Co.,Ltd.股价,Walvax Biotechnology Co.,Ltd.股市,Walvax Biotechnology Co.,Ltd.股票价格,Walvax Biotechnology Co.,Ltd.股票交易,Walvax Biotechnology Co.,Ltd.股票购买,Walvax Biotechnology Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Walvax Biotechnology Co.,Ltd.(300142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Walvax Biotechnology Co.,Ltd.(300142) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction